Literature DB >> 17868906

Recombined CC chemokine ligand 2 into B16 cells induces production of Th2-dominant [correction of dominanted] cytokines and inhibits melanoma metastasis.

Kaimeng Hu1, Jun Xiong, Kaihong Ji, Hongyu Sun, Jing Wang, Houqi Liu.   

Abstract

This study is aimed to verify whether CCL2 can induce Th2 polarization in vivo and subsequently inhibit tumor metastasis. B16 cells (a murine melanoma cell line) highly expressing CCL2 (CCL2-B16 cells) were obtained by transfection with recombinant plasmid CCL2-pcDNA3. Primary thymocytes were co-cultured with CCL2-B16 cells and STAT-6-mediated Th2 polarization was noticed after co-culture. Caudal vein injection of CCL2-B16 cells effectively inhibited pulmonary metastasis in C57BL/6 mice, but not in nude mice, indicating that T cells play a role in CCL2-induced inhibition of tumor metastasis. We found that high level of CCL2 up-regulated the expression of Th2-related cytokine (IL-4) in tumor microenvironment and increased CD4+, CD8+, and CD45RB+ cells in the peripheral blood and tumor tissues. We also demonstrated that inoculation of mice with CCL2-B16 cells prolonged mice survival time when they were reinjected with wildtype B16 cells, implying that CCL2 can activate immuno-memory in mice. It is concluded that high expression of CCL2 can induce Th2 polarization in tumor microenvironment and can effectively inhibit tumor metastasis, which casts new lights on the role of chemokines in reconstruction of immune surveillance in patients suffering from tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17868906     DOI: 10.1016/j.imlet.2007.07.004

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  8 in total

1.  Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells.

Authors:  Zvi G Fridlender; Veena Kapoor; George Buchlis; Guanjun Cheng; Jing Sun; Liang-Chuan S Wang; Sunil Singhal; Linda A Snyder; Steven M Albelda
Journal:  Am J Respir Cell Mol Biol       Date:  2010-04-15       Impact factor: 6.914

2.  CCL2 blockade augments cancer immunotherapy.

Authors:  Zvi G Fridlender; George Buchlis; Veena Kapoor; Guanjun Cheng; Jing Sun; Sunil Singhal; M Cecilia Crisanti; Cecilia Crisanti; Liang-Chuan S Wang; Daniel Heitjan; Linda A Snyder; Steven M Albelda
Journal:  Cancer Res       Date:  2009-12-22       Impact factor: 12.701

3.  Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

Authors:  Deborah A Knight; Shin Foong Ngiow; Ming Li; Tiffany Parmenter; Stephen Mok; Ashley Cass; Nicole M Haynes; Kathryn Kinross; Hideo Yagita; Richard C Koya; Thomas G Graeber; Antoni Ribas; Grant A McArthur; Mark J Smyth
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

4.  Chemokine CCL2/MCP-1 negatively regulates metastasis in a highly bone marrow-metastatic mouse breast cancer model.

Authors:  Munehisa Takahashi; Hiroshi Miyazaki; Mutsuo Furihata; Hirofumi Sakai; Takeo Konakahara; Morihiro Watanabe; Tomoko Okada
Journal:  Clin Exp Metastasis       Date:  2009-07-24       Impact factor: 5.150

Review 5.  The good and the bad of chemokines/chemokine receptors in melanoma.

Authors:  Ann Richmond; Jinming Yang; Yingjun Su
Journal:  Pigment Cell Melanoma Res       Date:  2009-02-14       Impact factor: 4.693

6.  Identification of Four Genes as Prognosis Signatures in Lung Adenocarcinoma Microenvironment.

Authors:  Yan Yao; Tingting Zhang; Lingyu Qi; Ruijuan Liu; Gongxi Liu; Jie Li; Changgang Sun
Journal:  Pharmgenomics Pers Med       Date:  2021-01-08

7.  Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition.

Authors:  Jessica Wenthe; Sedigheh Naseri; Ann-Charlotte Hellström; Rafael Moreno; Gustav Ullenhag; Ramon Alemany; Tanja Lövgren; Emma Eriksson; Angelica Loskog
Journal:  Mol Ther Oncolytics       Date:  2022-01-10       Impact factor: 7.200

Review 8.  Targeting the CCL2-CCR2 signaling axis in cancer metastasis.

Authors:  Su Yin Lim; Arseniy E Yuzhalin; Alex N Gordon-Weeks; Ruth J Muschel
Journal:  Oncotarget       Date:  2016-05-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.